Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10025 - 10032 of 12008 results
Court Dismisses Shareholder Derivative Action Targeting Directors and Officers for Data Breaches
October 22, 2014| Blog| Viewpoint
GAO Releases Report on CPSC Response to New and Emerging Hazards
October 21, 2014| Blog| Viewpoint
Join Our Webinar on Protecting Directors from Liability for Cybersecurity Risks
October 21, 2014| Blog| Viewpoint
Inter Partes Review Initial Filings of Paramount Importance: What Is Clear After Two Years of Inter Partes Review Under the AIA
October 21, 2014| Advisory| Viewpoint
Electronically Signing USPTO Papers: There’s a Rule for That
October 20, 2014| Blog| Viewpoint
Business Interruption Insurance for Ebola – Managing Risk for Hospitals and Healthcare Providers
October 20, 2014| Blog| Viewpoint
Supreme Court Examines Boundaries of Antitrust Immunity
October 20, 2014| Blog| Viewpoint
Keep Your Hands Off the Customers … and the Cows
October 17, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|